Targeting actin-bundling protein L-plastin as an anabolic therapy for bone loss

Abstract

The actin-bundling protein L-plastin (LPL) mediates the resorption activity of osteoclasts, but its therapeutic potential in pathological bone loss remains unexplored. Here, we report that LPL knockout mice show increased bone mass and cortical thickness with more mononuclear tartrate-resistant acid phosphatase–positive cells, osteoblasts, CD31hiEmcnhi endothelial vessels, and fewer multinuclear osteoclasts in the bone marrow and periosteum. LPL deletion impeded preosteoclasts fusion by inhibiting filopodia formation and increased the number of preosteoclasts, which release platelet-derived growth factor-BB to promote CD31hiEmcnhi vessel growth and bone formation. LPL expression is regulated by the phosphatidylinositol 3-kinase/AKT/specific protein 1 axis in response to receptor activator of nuclear factor–κB ligand. Furthermore, we identified an LPL inhibitor, oroxylin A, that could maintain bone mass in ovariectomy-induced osteoporosis and accelerate bone fracture healing in mice. In conclusion, we showed that LPL regulates osteoclasts fusion, and targeting LPL serves as a novel anabolic therapy for pathological bone loss.

Betaine Attenuates Osteoarthritis by Inhibiting Osteoclastogenesis and Angiogenesis in Subchondral Bone

“…Compounds with better retention behavior were expected to have stronger bonds with cell membrane receptors ( Chen et al, 2014 ; Ahmad Dar et al, 2020 ). We previously identified several active components by using the BMMC/CMC analytical system ( Gu et al, 2020 ; Li et al, 2020 ). In this study, BMMCs were used as target cells for screening potential compounds from the Lycii Radicis Cortex.…”

Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression

“…In this study we used 18 F-FMISO as a hypoxia probe and detected the hypoxia status of subchondral bone and cartilage through PET-CT in vivo. 18 F-FMISO based on the nitroimidazole structure, is the first hypoxia PET tracer used in clinical studies (41)(42)(43). 18 F-FMISO is reduced and covalently bound to intracellular macromolecules in hypoxic cells and will not escape from those cells (44).…”

Plastin 3 in X-Linked Osteoporosis: Imbalance of Ca2+-Dependent Regulation Is Equivalent to Protein Loss

“…(2) Contribution of PLS3 to bone resorption would be surprising given that osteoclasts as all cells of hematopoietic origin express PLS2 as the primary plastin isoform (Ma et al, 2010 ; Si et al, 2018 ; Li et al, 2020 ). Thus far, endogenous expression of PLS3 has not been clearly demonstrated in osteoclasts in vivo .…”